Harmony Biosciences Holdings, Inc.(HRMY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HRMY Harmony Biosciences Holdings, Inc.

盘后交易 04-28 18:50:57 EDT

31.16

+0.11

+0.35%

盘后31.16

+0.000.00%

16:20 EDT

最高31.46	最低30.63	成交量50.98万
今开31.34	昨收31.05	日振幅2.69%
总市值17.95亿	流通市值13.88亿	总股本5,760万
成交额1,579万	换手率1.14%	流通股本4,456万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HRMY","market":"US","secType":"STK","nameCN":"Harmony Biosciences Holdings, Inc.","latestPrice":31.16,"timestamp":1777406400000,"preClose":31.05,"halted":0,"volume":509754,"hourTrading":{"tag":"盘后","latestPrice":31.16,"preClose":31.16,"latestTime":"16:20 EDT","volume":21688,"amount":675786.498608,"timestamp":1777407647136,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.003542673107890481,"floatShares":44560063,"shares":57596358,"eps":2.71,"marketStatus":"盘后交易","change":0.11,"latestTime":"04-28 18:50:57 EDT","open":31.34,"high":31.46,"low":30.625,"amount":15791686.924826,"amplitude":0.026892,"askPrice":31.1,"askSize":100,"bidPrice":30.56,"bidSize":65,"shortable":3,"etf":0,"ttmEps":2.71,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1777420800000},"marketStatusCode":4,"adr":0,"listingDate":1597809600000,"exchange":"NASDAQ","adjPreClose":31.05,"preHourTrading":{"tag":"盘前","latestPrice":31.31,"preClose":31.05,"latestTime":"08:43 EDT","volume":71,"amount":2236.61999,"timestamp":1777380239643,"change":0.26,"changeRate":0.008374,"amplitude":0.031884},"postHourTrading":{"tag":"盘后","latestPrice":31.16,"preClose":31.16,"latestTime":"16:20 EDT","volume":21688,"amount":675786.498608,"timestamp":1777407647136,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.299917,"impliedVol":0.3231,"impliedVolPercentile":0.0757},"requestUrl":"/m/hq/s/HRMY","defaultTab":"news","newsList":[{"id":"1148574350","title":"Harmony Biosciences 任命新高管强化管理团队 并宣布董事会新增成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1148574350","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148574350?lang=zh_cn&edition=full","pubTime":"2026-04-02 20:05","pubTimestamp":1775131515,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings, Inc. 近日宣布两项重要人事变动，旨在加强公司治理与战略领导力。公司不仅新任命了一位核心高管加入其执行团队，还同时公布了董事会的新增成员名单。这一系列举措预计将为公司下一阶段的业务拓展与创新研发注入新的动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183532200","title":"异动解读 | 财报超预期且重申积极指引，Harmony Biosciences盘中大涨5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183532200","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183532200?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:57","pubTimestamp":1771945063,"startTime":"0","endTime":"0","summary":"生物制药公司Harmony Biosciences Holdings, Inc.（HRMY）今日盘中股价大幅上涨5.28%，引起市场关注。消息面上，公司于盘前披露了2025年度财务业绩，表现显著超出市场预期。同时，公司管理层重申了对2026财年的积极展望，预计净收入将突破10亿美元大关。强劲的财报数据和乐观的未来指引，增强了投资者对公司增长潜力的信心，从而推动了股价的上涨。财务数据显示，公司在2025年实现了强劲的收入增长与盈利能力提升，主要得益于核心产品市场的持续扩张及运营效率的优化。管理层在业绩说明中强调，这一成果为2026年的战略目标奠定了坚实基础。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133977025","title":"Harmony Biosciences公布2025年强劲财报，重申2026年净收入指引超10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133977025","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133977025?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:31","pubTimestamp":1771936273,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings, Inc.（简称Harmony Biosciences）近日披露了其2025年度财务业绩，表现显著超出市场预期。公司同时重申了对2026财年的积极展望，预计净收入将突破10亿美元大关。\n财务数据显示，公司在2025年实现了强劲的收入增长与盈利能力提升，主要得益于核心产品市场的持续扩张及运营效率的优化。管理层在业绩说明中强调，这一成果为2026年的战略目标奠定了坚实基础。\n基于当前业务势头与管线进展，Harmony Biosciences确认2026年净收入指引维持在10亿美元以上，反映出管理层对业务增长潜力的坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103571364","title":"Harmony Biosciences获FDA批准Wakix®（Pitolisant）用于治疗儿童发作性睡病中的猝倒症","url":"https://stock-news.laohu8.com/highlight/detail?id=1103571364","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103571364?lang=zh_cn&edition=full","pubTime":"2026-02-17 21:07","pubTimestamp":1771333620,"startTime":"0","endTime":"0","summary":"美国生物制药公司Harmony Biosciences Holdings, Inc.（简称Harmony Biosciences）近日宣布，其研发的Wakix®（Pitolisant）已获得美国食品药品监督管理局（FDA）的批准，新增用于治疗儿科患者发作性睡病中的猝倒症。这一重要监管决定标志着该药物在儿童患者群体中的应用获得扩展，为患有此罕见睡眠障碍的年轻患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134367713","title":"财报前瞻 ｜Harmony Biosciences Holdings, Inc.营收预计增19.55%，共识乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1134367713","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134367713?lang=zh_cn&edition=full","pubTime":"2026-02-17 12:11","pubTimestamp":1771301517,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings, Inc.将于2026年02月24日美股盘前发布最新季度财报，市场关注营收增长与盈利质量的延续性。市场一致预期本季度公司营收为2.40亿美元，同比增19.55%；调整后每股收益为0.90美元，同比增22.09%；息税前利润为6,752.37万美元，同比增8.64%。上一季度公司营收为2.39亿美元，同比增28.71%；毛利率为75.09%；归属于母公司股东的净利润为5,086.50万美元，净利率为21.24%；调整后每股收益为0.87美元，同比增10.13%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜Harmony Biosciences Holdings, Inc.营收预计增19.55%，共识乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124621725","title":"Beacon Biosignals与Harmony Biosciences达成合作，推进嗜睡症客观临床终点的量化脑电图研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1124621725","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124621725?lang=zh_cn&edition=full","pubTime":"2025-12-16 19:30","pubTimestamp":1765884625,"startTime":"0","endTime":"0","summary":"Beacon Biosignals与Harmony Biosciences达成合作，推进嗜睡症客观临床终点的量化脑电图研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112131006","title":"Harmony Biosciences股价在盘前上涨2%，因公司公布睡眠障碍药物研究的积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1112131006","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112131006?lang=zh_cn&edition=full","pubTime":"2025-11-24 21:30","pubTimestamp":1763991010,"startTime":"0","endTime":"0","summary":"Harmony Biosciences股价在盘前上涨2%，因公司公布睡眠障碍药物研究的积极结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115749473","title":"Harmony Biosciences公布皮托利桑胃耐药制剂的关键生物等效性研究积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1115749473","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115749473?lang=zh_cn&edition=full","pubTime":"2025-11-24 21:06","pubTimestamp":1763989587,"startTime":"0","endTime":"0","summary":"Harmony Biosciences公布皮托利桑胃耐药制剂的关键生物等效性研究积极结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152307477","title":"Harmony Biosciences启动首个针对中枢性嗜睡障碍的首个人体研究，探索潜在最佳Orexin 2受体激动剂(BP1.15205)","url":"https://stock-news.laohu8.com/highlight/detail?id=1152307477","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152307477?lang=zh_cn&edition=full","pubTime":"2025-11-19 21:07","pubTimestamp":1763557633,"startTime":"0","endTime":"0","summary":"Harmony Biosciences启动首个针对中枢性嗜睡障碍的首个人体研究，探索潜在最佳Orexin 2受体激动剂(BP1.15205)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156433251","title":"异动解读 | Harmony Biosciences盘中大涨5.01%，强劲财报及患者数量增加提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1156433251","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156433251?lang=zh_cn&edition=full","pubTime":"2025-11-05 04:32","pubTimestamp":1762288324,"startTime":"0","endTime":"0","summary":"生物科技公司Harmony Biosciences Holdings, Inc.今日盘中大涨5.01%，投资者对公司最新发布的强劲财报及业务增长表现出积极反应。根据公司最新公布的2025年第三季度财报，Harmony Biosciences的平均患者数量创下新高，较上一季度增加约500人，达到8,100人。分析人士指出，Harmony Biosciences的业务表现优于预期，尤其是在患者数量增长和收入指引上调方面的亮眼表现，极大地提振了投资者信心。这些积极因素共同推动了公司股价的显著上涨，反映出市场对Harmony Biosciences未来发展前景的看好。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132638287","title":"Harmony Biosciences: 平均患者数量创纪录增加约500人，第三季度达8,100人","url":"https://stock-news.laohu8.com/highlight/detail?id=1132638287","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132638287?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:33","pubTimestamp":1762259598,"startTime":"0","endTime":"0","summary":"Harmony Biosciences: 平均患者数量创纪录增加约500人，第三季度达8,100人","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120867704","title":"Harmony Biosciences发布2025年第三季度强劲财报；近期将2025年收入指引上调至8.45亿-8.65亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120867704","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120867704?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:31","pubTimestamp":1762259516,"startTime":"0","endTime":"0","summary":"Harmony Biosciences发布2025年第三季度强劲财报；近期将2025年收入指引上调至8.45亿-8.65亿美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516504665","title":"Harmony Biosciences Holdings, Inc.盘中异动 临近收盘股价大跌5.02%报32.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516504665","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516504665?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:52","pubTimestamp":1741035141,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时52分，Harmony Biosciences Holdings, Inc.股票出现异动，股价快速下跌5.02%。Harmony Biosciences Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.13%。Harmony Biosciences Holdings, Inc.公司简介：Harmony Biosciences Holdings Inc是一家商业阶段的制药公司，致力于为患有罕见的神经系统疾病且未满足医疗需求的患者开发和商业化创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304045221a25da95c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304045221a25da95c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516255734","title":"Harmony Biosciences Holdings, Inc.2024财年实现净利润1.45亿美元，同比增加12.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516255734","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516255734?lang=zh_cn&edition=full","pubTime":"2025-03-02 00:00","pubTimestamp":1740844858,"startTime":"0","endTime":"0","summary":"3月2日，Harmony Biosciences Holdings, Inc.公布财报，公告显示公司2024财年净利润为1.45亿美元，同比增加12.40%；其中营业收入为7.15亿美元，同比增加22.85%，每股基本收益为2.56美元。机构评级：截至2025年3月2日，当前有9家机构对Harmony Biosciences Holdings, Inc.目标价做出预测，其中目标均价为51.67美元，其中最低目标价为33.00美元，最高目标价为70.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000114a259dc9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000114a259dc9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130460807","title":"异动解读 | Harmony Biosciences Holdings股价盘中大涨5.02%,财报业绩超预期推动","url":"https://stock-news.laohu8.com/highlight/detail?id=1130460807","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130460807?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:32","pubTimestamp":1740511954,"startTime":"0","endTime":"0","summary":"罕见神经疾病制药公司Harmony Biosciences Holdings, Inc.盘中股价大涨5.02%,引发市场关注。\n\n数据显示,公司季度每股收益为1.08美元,超出分析师预期的0.74美元。营收同比增长19.5%至2.0127亿美元,也高于华尔街预期。其主打产品Wakix睡眠障碍药物的销售额达2.013亿美元,表现强劲。\n\n分析人士指出,Harmony Biosciences财报业绩出色主要得益于产品线销售增长,证明公司在罕见疾病治疗领域具备强劲竞争力。同时较高的销售及利润增长预期也支撑了股价上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514437070","title":"Harmony Biosciences Holdings, Inc.盘中异动 股价大涨5.02%报35.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514437070","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514437070?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:31","pubTimestamp":1740511866,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日03时31分，Harmony Biosciences Holdings, Inc.股票出现波动，股价快速拉升5.02%。Harmony Biosciences Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。Harmony Biosciences Holdings, Inc.公司简介：Harmony Biosciences Holdings Inc是一家商业阶段的制药公司，致力于为患有罕见的神经系统疾病且未满足医疗需求的患者开发和商业化创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226033106989284e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226033106989284e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109664135","title":"Harmony Biosciences第四季度调整后每股收益$1.08超过预期$0.74， 销售额$2.0127亿超过预期$2.0125亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1109664135","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109664135?lang=zh_cn&edition=full","pubTime":"2025-02-25 20:42","pubTimestamp":1740487368,"startTime":"0","endTime":"0","summary":"Harmony Biosciences  报告季度每股收益为$1.08，高于分析师预期的$0.74，超出45.95%。该公司报告的季度销售额为$2.0127亿，超过了分析师预期的$2.0125亿，仅超出0.01%。这比去年同期的$1.6841亿销售额增加了19.51%。以上内容来自Benzinga Earnings专栏，原文如下：Harmony Biosciences  reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.74 by 45.95 percent. This is a 47.95 percent increase over earnings of $0.73 per share from the same period last year.  The company reported quarterly sales of $201.27 million which beat the analyst consensus estimate ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Harmony Biosciences第四季度调整后每股收益$1.08超过预期$0.74， 销售额$2.0127亿超过预期$2.0125亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512866483","title":"Harmony Biosciences Holdings, Inc.盘中异动 早盘急速跳水5.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512866483","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512866483?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:31","pubTimestamp":1739975473,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时31分，Harmony Biosciences Holdings, Inc.股票出现波动，股价大幅跳水5.82%。Harmony Biosciences Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.15%。Harmony Biosciences Holdings, Inc.公司简介：Harmony Biosciences Holdings Inc是一家商业阶段的制药公司，致力于为患有罕见的神经系统疾病且未满足医疗需求的患者开发和商业化创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223113a24bf91b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223113a24bf91b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511520181","title":"Harmony Biosciences Holdings, Inc.盘中异动 股价大涨5.07%报39.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511520181","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511520181?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:02","pubTimestamp":1739466149,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日01时02分，Harmony Biosciences Holdings, Inc.股票出现波动，股价快速上涨5.07%。Harmony Biosciences Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.77%。Harmony Biosciences Holdings, Inc.公司简介：Harmony Biosciences Holdings Inc是一家商业阶段的制药公司，致力于为患有罕见的神经系统疾病且未满足医疗需求的患者开发和商业化创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502140102309621d99e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502140102309621d99e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HRMY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510358115","title":"Harmony Biosciences(HRMY.US)获德银首次覆盖，给予买入评级, 目标价55.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510358115","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510358115?lang=zh_cn&edition=full","pubTime":"2025-02-12 02:11","pubTimestamp":1739297470,"startTime":"0","endTime":"0","summary":"Harmony Biosciences(HRMY.US)获德银首次覆盖，给予买入评级, 目标价55.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12021148092644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HRMY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.harmonybiosciences.com","stockEarnings":[{"period":"1week","weight":0.0515},{"period":"1month","weight":0.1699},{"period":"3month","weight":-0.176},{"period":"6month","weight":0.059},{"period":"1year","weight":0.0486},{"period":"ytd","weight":-0.1702}],"compareEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":0.1279},{"period":"3month","weight":0.0283},{"period":"6month","weight":0.0404},{"period":"1year","weight":0.2988},{"period":"ytd","weight":0.0488}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Harmony Biosciences Holdings, Inc.于2017年7月25日成立，是一家商业阶段的制药公司，致力于为患有罕见的神经系统疾病且未满足医疗需求的患者开发和商业化创新疗法。该公司的产品WAKIX（pitolisant）是具有新颖作用机制或MOA的一流分子，专门设计用于通过与H3受体结合来增强大脑中的组胺信号传导。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.035612},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.051691},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.016911},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.04717},{"month":5,"riseRate":0.6,"avgChangeRate":0.050645},{"month":6,"riseRate":0.6,"avgChangeRate":-0.007672},{"month":7,"riseRate":0.8,"avgChangeRate":0.041515},{"month":8,"riseRate":0.8,"avgChangeRate":0.05943},{"month":9,"riseRate":0.5,"avgChangeRate":-0.023406},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.006378},{"month":11,"riseRate":0.833333,"avgChangeRate":0.105341},{"month":12,"riseRate":0.5,"avgChangeRate":0.02881}],"exchange":"NASDAQ","name":"Harmony Biosciences Holdings, Inc.","nameEN":"Harmony Biosciences Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Harmony Biosciences Holdings, Inc.(HRMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Harmony Biosciences Holdings, Inc.(HRMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Harmony Biosciences Holdings, Inc.,HRMY,Harmony Biosciences Holdings, Inc.股票,Harmony Biosciences Holdings, Inc.股票老虎,Harmony Biosciences Holdings, Inc.股票老虎国际,Harmony Biosciences Holdings, Inc.行情,Harmony Biosciences Holdings, Inc.股票行情,Harmony Biosciences Holdings, Inc.股价,Harmony Biosciences Holdings, Inc.股市,Harmony Biosciences Holdings, Inc.股票价格,Harmony Biosciences Holdings, Inc.股票交易,Harmony Biosciences Holdings, Inc.股票购买,Harmony Biosciences Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Harmony Biosciences Holdings, Inc.(HRMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Harmony Biosciences Holdings, Inc.(HRMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}